| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Introduction
The United States stands in stark contrast to Europe and Japan in terms of the
freedom that manufacturers have to set-and increase-the prices of branded
drugs in the U.S. market. However, pharmaceutical companies need to give
careful thought to their pricing strategies in all markets. Payers around the
world are constantly adjusting their pharmaceutical cost-containment
strategies.
Get the Answers You Need to Shape Your Strategy
- Leading pharmaceutical benefi t management companies (PBMs) in the United
States are seeking new ways to contain prescription drug costs. How do
recent pricing trends for generics and branded drugs compare? What are PBMs
doing to stimulate greater use of generics? What is the outlook for specialty
pharmaceuticals?
- The French government has announced a major new cost-containment
initiative. How will the government's medical control strategy be used to
save €500 million ($684 million) per year? Which categories of drugs are
likely to be targets for price cuts? Which drug class could be subjected to
reimbursement at the price level of generics?
- German health insurance funds recently cut reference prices in 59
reference pricing groups. How many products now exceed their reference
prices? What impact have the reference price cuts had on the availability of
copayment-exempt drugs?
- The U.K. government has unveiled a new drug pricing and reimbursement
system and a constitution for the National Health Service. What effect will
the new Pharmaceutical Price Regulation Scheme have on U.K. drug prices? How
does the government plan to stimulate pharmaceutical innovation? How is the
role of the National Institute for Health and Clinical Excellence (NICE)
likely to change?
Scope
- Issues affecting the pharmaceutical industry in the United States:
recent spending trends; pricing; increasing use of generics; specialty
pharmacy; Medicare reforms; new active surveillance system.
- Issues affecting the pharmaceutical industry in Europe: expansion
of European Commission antitrust investigation; French government's new
cost-containment strategy; impact of German reference pricing cuts; Italian
prescribing trends; steady growth in the Spanish prescription drug market;
price cuts agreed in negotiations for new U.K. drug pricing system.
- Issues affecting the pharmaceutical industry in Japan: industry
association's proposed new pricing system; unprecedented focus on expanding
the generics market.
TABLE OF CONTENTS
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- United States
- Pharmacy Benefi t Management Trends
- Recent Spending Trends
- Pricing
- Increasing Use of Generics
- Specialty Pharmacy
- Outlook
- Medicare Reforms
- Approval of New Active Surveillance System
- European Union
- Expansion of European Commission's Antitrust Investigation
- France
- Impact of New Patient Charge
- Call for a Review of the Prescription, Consumption, and Taxation of
Medicines
- Rollout of Personal Medical Dossiers Extended
- Government Plan for a Major New Cost-Containment Strategy
- Germany
- Rapid Growth of Rebate Contracts
- Impact of Reference Price Cuts
- Clarifi cation of Second Opinion Process
- Italy
- Prescribing Trends in 2007
- Spain
- New Government Health Plan
- Strongest Sales Growth for High-Priced Drugs
- Steady Growth in the Prescription Drug Market
- United Kingdom
- Tentative Agreement on Price Cuts in Negotiations for New Drug Pricing
System
- Promise of Improved Market Access for Innovative Medicines
- Growing Industry Disillusionment with the U.K. Market
- Initiative to Increase the Use of Statins
- Eisai's Legal Victory over NICE
- Japan
- Industry Proposal for a New Drug Pricing System
- Unprecedented Focus on Expanding the Generics Market
- Outlook and Implications for the Pharmaceutical Industry
Figures
- 1. Leading PBMs' Growth Rates for Per Member Per Month Spending on
Specialty Pharmaceuticals and Prescription Drugs Overall, 2007
- 2. Leading PBMs' Reported Changes in Drug Prices, 2007
- 3. Express Scripts' Reported Changes in Average Prices of Select Drug
Classes, 2007
- 4. Leading PBMs' Generics Dispensing Rates, 2006-2007
- 5. Express Scripts' Calculations of Actual and Potential Generics
Dispensing Rates and Potential Savings, 2007
- 6. Express Scripts' Projected Growth Rates for Per Member Per Month
Spending on Specialty and Nonspecialty Drugs, 2008-2011
- 7. Distribution of Rebate Contracts in Germany, April 2008
- 8. Pharmaceutical Consumption in Italy, 2003-2007
- 9. Pharmaceutical Spending in Italy, 2003-2007
- 10. Contribution of Changes in Prescribing Volume, Drug Price, and Product
Mix to Overall Spending Trends for Fully Reimbursed Drugs in Italy, 2003-2007
- 11. Generics' and Off-Patent Branded Drugs' Share of Spending on Fully
Reimbursed Drugs in Italy, 2003-2007
- 12. Spanish Pharmaceutical Market Trends by Product Price Range, 2001-2006
- 13. Generics' Share of the Japanese Pharmaceutical Market, 2002-2006
|
